Glioblastoma Drug Discovery
Photo credit: ThisisEngineering RAEng

Although genomics has provided a mass of molecular information to investigate the aetiology of cancer, most cancers still lack adequate long-term, sustainable therapy. This is especially so for glioblastoma, which is characterised by a relatively small and dispersed patient population, and highly specialised and often novel treatment regimens (requiring the engagement of regulatory authorities during development).

Glioblastoma multiforme (GBM) is a phenotypically complex and challenging disease to treat. Nevertheless, recent advances in GBM research, give us considerable hope of applying new phenotypic screening methods for patient diagnosis, follow-up and treatment evaluation, revealing therapeutic options so far missed in treating this challenging rare disease.

With this challenging remit, GBM drug discovery requires the development of sophisticated and novel tools and technologies. At IOTA we are developing three themes to address these challenges:
cell libraries that are genetically and clinically annotated from which to develop cell-based approaches to new drug discovery in a personalised, patient-centric context.
Novel diagnostic methodologies
and protocols, targeting individual patient populations and validated in patient-derived chemical biology platforms.
Fostering close collaborations
to establish lab-to-clinic pipelines with a clear trajectory towards efficient patient delivery of candidate therapies.